Outside the U.S. stock markets are recovery much more quickly, in turn causing more investors to put their money overseas.

Money is pouring into biotech firms right now. That's bad news for investors, who are paying high prices for stocks that offer at best mixed results, writes Brett Arends.

A number of companies appear to be in such a hurry to file for IPOs that they have dispensed with the formality of selecting which exchange, or even, in some cases, the names of the underwriters they want on their deals.

Now may be a good time for many investors to consider a tax-planning move known as tax-loss harvesting.

While Canadian banking shares trade at a premium to many rival bank stocks -- they're worth it.

IPOs still draw plenty of attention, but lately investors don't seem to buy in like they used to.

Value-oriented funds have taken the lead in recent months, but many pros now see brighter prospects for funds that invest in fast-expanding businesses.

Learn the warning signs, and you'll see the next bubble before it bursts.

Some companies are running out of shares for their employee stock purchase plans.

Buy-and-hold stock investors have suffered though a market that has produced zero gains over the past decade. But diversified investors, even those whose stock portion was in the U.S. market, fared slightly better.